A phase III comparative study to evaluate the efficacy and safety of SJP-0125 versus brimonidine tartrate in patients with primary open-angle glaucoma or ocular hypertension
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2019
Price : $35 *
At a glance
- Drugs SJP-0125 (Primary) ; Brimonidine
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Senju Pharmaceutical
- 04 Feb 2019 Status changed from recruiting to completed.
- 17 Nov 2017 Status changed from not yet recruiting to recruiting.
- 19 Sep 2017 New trial record